AMRX icon

Amneal Pharmaceuticals

7.97 USD
-0.27
3.28%
At close Jul 18, 4:00 PM EDT
After hours
7.97
+0.00
0.00%
1 day
-3.28%
5 days
-3.98%
1 month
0.38%
3 months
11.78%
6 months
-6.89%
Year to date
2.71%
1 year
8.88%
5 years
69.94%
10 years
-46.90%
 

About: Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 8,100

0
Funds holding %
of 7,321 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

279% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 14

168% more call options, than puts

Call options by funds: $3.18M | Put options by funds: $1.19M

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]

70% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 53

19% more funds holding

Funds holding: 197 [Q4 2024] → 234 (+37) [Q1 2025]

13% more capital invested

Capital invested by funds: $997M [Q4 2024] → $1.13B (+$129M) [Q1 2025]

2.26% more ownership

Funds ownership: 40.64% [Q4 2024] → 42.9% (+2.26%) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for AMRX.

Financial journalist opinion

Based on 4 articles about AMRX published over the past 30 days

Neutral
GlobeNewsWire
9 hours ago
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada.
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
Neutral
GlobeNewsWire
1 week ago
Amneal to Report Second Quarter 2025 Results on August 5, 2025
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial results on Tuesday, August 5, 2025, prior to market open.
Amneal to Report Second Quarter 2025 Results on August 5, 2025
Positive
Zacks Investment Research
2 weeks ago
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Neutral
GlobeNewsWire
3 weeks ago
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC.
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Negative
Zacks Investment Research
1 month ago
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Neutral
GlobeNewsWire
1 month ago
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
Neutral
GlobeNewsWire
1 month ago
Amneal to Participate at Upcoming Investor Conferences in June
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events.
Amneal to Participate at Upcoming Investor Conferences in June
Positive
Zacks Investment Research
1 month ago
3 Reasons Growth Investors Will Love Amneal (AMRX)
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
3 Reasons Growth Investors Will Love Amneal (AMRX)
Positive
Reuters
2 months ago
US FDA approves Amneal's migraine treatment
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
US FDA approves Amneal's migraine treatment
Charts implemented using Lightweight Charts™